Berlin - Berlin Delayed Price. Currency in EUR
0.28-0.01 (-2.08%)
At close: 2:08 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.29
Bid0.00 x
Ask0.00 x
Day's Range0.28 - 0.28
52wk Range0.22 - 0.46
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
Avg Vol (3m)0
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Benzinga3 days ago

    Mast Therapeutics Provides Clinical Developments Update; Range-Bound Trading A Mid-Term Plausibility

    On Monday, Mast Therapeutics Inc (NYSE: MSTX ) provided an update on its business strategy and the clinical development of its product candidate AIR001. Laidlaw’s Yale Jen maintains a Neutral rating on ...

  • PR Newswire4 days ago

    Mast Therapeutics Provides Business Update

    SAN DIEGO, Sept. 26, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided an update related to its business strategy and the clinical development of its product candidates. The Company's cash, cash equivalents, and investment securities were $30.3 million at August 31, 2016. The Company will focus on clinical development of AIR001 (sodium nitrite solution for intermittent inhalation) for the treatment of heart failure with preserved ejection fraction (HFpEF).  Specifically, during 2016 and 2017, the Company will continue to support three ongoing investigator-sponsored Phase 2 clinical studies of AIR001 being conducted at prestigious research institutions.

  • Investopedia8 days ago

    Mast Therapeutics Crash Led By Poor Results (MSTX)

    The company's shares have suffered in the wake of failed drug studies that forced it to cancel clinical development plans